You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨新冠疫苗股普跌 隔夜美股疫苗股重挫
格隆匯1月19日丨疫苗股普跌,中國中藥跌近5%,康希諾跌逾4%。隔夜美股疫苗股重挫,BioNTech大跌13.66%,諾瓦瓦克斯跌逾11%,莫德納跌近9%。以色列舍巴醫療中心傳染病部門負責人Gili Regev-Yochay稱,在為該醫療中心的154名醫務人員接種第四劑輝瑞新冠疫苗兩週後,試驗對象體內的抗體水平有所提高。試驗數據仍然表明第四針疫苗對於預防重症方面有顯著效果,注射了第四針新冠疫苗而仍舊感染奧密克戎病毒的試驗人羣只有輕微的症狀或者無症狀。且與對照組相比,接種疫苗第四針的人感染率略低一點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account